MAP2K1 Gene

Migration, Crosslink

📖

MAP2K1 Gene

active

wiki page Created: 2026-04-02T07:19:28 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-genes-map2k1

📖 Wiki Page

gene1270 wordssynced 2026-04-02

MAP2K1 — Mitogen-Activated Protein Kinase Kinase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MAP2K1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAP2K1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Mitogen-Activated Protein Kinase Kinase 1</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>MEK1, MEK, PRKMK1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q22.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5604</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000169032</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q02750</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>176872</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Dual specificity mitogen-activated protein kinase kinase 1 (MEK1)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>43 kDa</td>
</tr>
<tr>
<td class="label">Amino Acids</td>
<td>393 amino acids</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, nucleus (upon activation)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>MAP2K family (MAP kinases)</td>
</tr>
<tr>
<td class="label">Catalytic Activity</td>
<td>Dual-specificity kinase ( phosphorylates Tyr and Thr)</td>
</tr>
<tr>
<td

...

MAP2K1 — Mitogen-Activated Protein Kinase Kinase 1

<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">MAP2K1 Gene</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>MAP2K1</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Mitogen-Activated Protein Kinase Kinase 1</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>MEK1, MEK, PRKMK1</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>15q22.31</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>5604</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000169032</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>Q02750</td>
</tr>
<tr>
<td class="label">OMIM</td>
<td>176872</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Protein Name</td>
<td>Dual specificity mitogen-activated protein kinase kinase 1 (MEK1)</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>43 kDa</td>
</tr>
<tr>
<td class="label">Amino Acids</td>
<td>393 amino acids</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, nucleus (upon activation)</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>MAP2K family (MAP kinases)</td>
</tr>
<tr>
<td class="label">Catalytic Activity</td>
<td>Dual-specificity kinase ( phosphorylates Tyr and Thr)</td>
</tr>
<tr>
<td class="label">Approach</td>
<td>Agent</td>
</tr>
<tr>
<td class="label">MEK inhibition</td>
<td>Selumetinib</td>
</tr>
<tr>
<td class="label">RAF inhibition</td>
<td>Sorafenib</td>
</tr>
<tr>
<td class="label">ERK inhibition</td>
<td>FR180204</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Original Indication</td>
</tr>
<tr>
<td class="label">Selumetinib</td>
<td>Cancer</td>
</tr>
<tr>
<td class="label">Trametinib</td>
<td>Cancer</td>
</tr>
<tr>
<td class="label">PD98059</td>
<td>Research</td>
</tr>
<tr>
<td class="label">Binimetinib</td>
<td>Cancer</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/cancer" style="color:#ef9a9a">Cancer</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a>, <a href="/wiki/tumor" style="color:#ef9a9a">Tumor</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">62 edges</a></td>
</tr>
</table>

Overview

Mermaid diagram (expand to render)

MAP2K1 (Mitogen-Activated Protein Kinase Kinase 1) encodes MEK1 (also known as MAP2K1), a dual-specificity serine/threonine kinase that serves as a critical intermediate in the RAS-RAF-MEK-ERK (MAPK) signaling cascade. MEK1 phosphorylates and activates ERK1/2 (Extracellular Signal-Regulated Kinases), linking upstream RAF kinase signaling to downstream cellular responses including gene expression, cell proliferation, and synaptic plasticity["@rosenzweig2018"].

In the central nervous system, MEK1-ERK signaling is essential for neuronal development, synaptic plasticity, long-term potentiation (LTP), learning, and memory formation. Dysregulated MEK-ERK signaling is strongly implicated in the pathogenesis of Alzheimer's disease (AD), Parkinson's disease (PD), and various psychiatric disorders. Germline mutations in MAP2K1 cause Cardiofaciocutaneous Syndrome (CFC) and Noonan Syndrome, developmental disorders that highlight the critical importance of this kinase in normal growth and neural development["@arthur2011"].

Gene Information

Protein Overview

Protein Structure

MEK1 possesses several functional domains essential for its enzymatic activity and regulation:

N-terminal Regulatory Region (residues 1-70): Contains a proline-rich region and binding sites for upstream regulators
Kinase Domain (residues 71-308): Catalytic core with dual-specificity kinase activity
C-terminal Region (residues 309-393): Contains ERK docking sites and nuclear localization signals

Key Structural Features:

ATP-binding pocket: Targeted by MEK inhibitors (e.g., selumetinib, trametinib)
Phosphorylation sites: Ser218, Ser222, and Thr286 are essential for full activation
D-motifs: ERK docking motifs for substrate recognition

Normal Physiological Functions

Neuronal Development

During CNS development, MEK1-ERK signaling regulates[@rosenzweig2018]:

Neuronal Proliferation: Controls cell cycle exit and neuronal differentiation

Axonal Guidance: Regulates growth cone dynamics and pathfinding

Dendritogenesis: Shapes dendritic arbor morphology

Synaptogenesis: Facilitates synaptic connection formation

Synaptic Plasticity

MEK-ERK signaling is a central mediator of activity-dependent synaptic plasticity[@reimers2014]:

Long-term Potentiation (LTP): ERK activation is required for LTP induction and maintenance
Long-term Depression (LTD): Regulates AMPA receptor internalization
Synaptic Scaling: Controls homeostatic plasticity responses
Memory Consolidation: Essential for converting short-term to long-term memory

Cellular Survival

MEK1-ERK signaling promotes neuronal survival through:

Anti-apoptotic signaling: Phosphorylation of BAD, caspase inhibition
Metabolic regulation: Glucose uptake, mitochondrial function
Stress response: Oxidative stress protection
Growth factor signaling: BDNF, NGF signaling pathways

Role in Alzheimer's Disease

MAPK Pathway Dysregulation

The MEK-ERK signaling pathway is profoundly dysregulated in AD brains[@kim2015]:

Hyperactive ERK in AD:

Elevated phospho-ERK levels in vulnerable brain regions
Correlates with neurofibrillary tangle burden
Associated with cognitive decline

Mechanisms of Dysregulation:

Amyloid-beta (Aβ) oligomers activate upstream RAF kinases
Chronic activation leads to synaptic dysfunction
Alters tau phosphorylation through GSK-3β crosstalk

Therapeutic Implications

MEK-ERK pathway represents a therapeutic target in AD[@xia2016][@zhou2016]:

Challenges:

Complex biphasic role of ERK (neuroprotective vs. pathological)
Required for normal cognitive function
Narrow therapeutic window

Molecular Interactions

In AD, MEK-ERK interacts with:

Amyloid precursor protein (APP) processing
Tau phosphorylation through GSK-3β
Synaptic proteins (AMPA, NMDA receptors)
Transcription factors (CREB, c-Fos)

Role in Parkinson's Disease

Dopaminergic Neuron Vulnerability

MEK-ERK signaling is altered in PD pathogenesis[@kim2016]:

Changes in PD Brain:

Dysregulated MEK-ERK in substantia nigra
Altered response to dopaminergic neuron loss
Interaction with alpha-synuclein pathology

Mechanisms:

Oxidative stress activates MEK-ERK
Neuroinflammation drives chronic activation
Mitochondrial dysfunction affects pathway regulation

Neuroprotective Strategies

MEK inhibitors show neuroprotective potential in PD models[@wang2017]:

Selumetinib: Protects dopaminergic neurons in toxin models
Trametinib: Reduces neuroinflammation
PD98059: Improves mitochondrial function

Considerations:

Timing of intervention critical
May interfere with compensatory responses
Needs targeted CNS delivery

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Activated in motor neurons of ALS patients
Contributes to excitotoxicity
MEK inhibitors under investigation

Huntington's Disease (HD)

Mutant huntingtin affects MEK-ERK signaling
Contributes to transcriptional dysregulation
MEK inhibition improves phenotype in models

Frontotemporal Dementia (FTD)

Tau pathology affects MAPK pathway
Alters synaptic function
Therapeutic targeting being explored

Genetic Disorders

Cardiofaciocutaneous Syndrome (CFC)

Germline missense mutations in MAP2K1 cause CFC:

Inheritance: Autosomal dominant (de novo)
Features: Cardiac defects, facial dysmorphism, developmental delay
Neurological: Variable intellectual disability, seizures
Cancer Risk: Increased risk of hematologic malignancies

Noonan Syndrome

MAP2K1 is one of several genes causing Noonan Syndrome:

Characteristic Features: Short stature, webbed neck, cardiac defects
Neurological: Learning difficulties, autism spectrum disorder
Treatment: MEK inhibitors (e.g., trametinib) show efficacy

Therapeutic Targeting

MEK Inhibitors in Neurodegeneration

Clinical Trials

Several trials explore MEK inhibition in neurodegeneration:

NCT03726710: Selumetinib in plexiform neurofibromas (not CNS)

NCT03475953: Trametinib in various indications

Ongoing trials in AD and PD using MEK inhibitors

Biomarkers

Phospho-ERK levels: Measure pathway activation
CSF biomarkers: Under development
PET ligands: MEK inhibitor-based imaging probes

Signaling Cascade

Growth Factors, neurotransmitters
↓
RAS (HRAS/NRAS/KRAS)
↓
RAF (ARAF/BRAF/CRAF)
↓
MEK1/2 (MAP2K1/MAP2K2)
↓
ERK1/2 (MAPK1/MAPK3)
↓
Gene Expression, Cell Growth,
Synaptic Plasticity, Survival

Cross-references

[MAPK Signaling Pathway](/mechanisms/mapk-signaling-neurodegeneration)
[ERK Signaling](/mechanisms/erk-signaling-pathway)
[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Synaptic Plasticity Mechanisms](/mechanisms/synaptic-plasticity)
[MEK Protein Family](/proteins/mek-protein)
[RAF Kinases](/proteins/raf-kinases)
[Tau Pathology](/mechanisms/tau-pathology)
[Alpha-Synuclein Pathology](/mechanisms/alpha-synuclein-pathology)

External Links

[NCBI Gene Database - MAP2K1](https://www.ncbi.nlm.nih.gov/gene/5604)
[UniProt - MEK1 (Q02750)](https://www.uniprot.org/uniprot/Q02750)
[OMIM - MAP2K1](https://www.omim.org/entry/176872)
[ClinicalTrials.gov - MEK inhibitors](https://clinicaltrials.gov/?term=MEK+inhibitor+neurodegeneration)

References

[Rosenzweig et al., MAPK signaling in brain development and cognitive function (2018)](https://pubmed.ncbi.nlm.nih.gov/30523332/). Comprehensive review of MAPK pathway in CNS development and cognition.

[Arthur et al., MEK function in neuronal physiology and pathogenesis (2011)](https://pubmed.ncbi.nlm.nih.gov/22131410/). Reviews MEK1's role in normal brain function and disease.

[Kim & Choi, ERK/MAPK signaling in Alzheimer disease pathogenesis (2015)](https://pubmed.ncbi.nlm.nih.gov/26791816/). Documents ERK dysregulation in AD brain.

[Zhou et al., MEK inhibitors in neurodegenerative disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26875552/). Reviews therapeutic potential of MEK inhibition.

[Pearson et al., MAP kinase pathways in neurodegeneration (2015)](https://pubmed.ncbi.nlm.nih.gov/25616554/). Overview of MAPK pathway alterations across neurodegenerative diseases.

[Xia et al., Targeting MAPK pathways in AD and PD (2016)](https://pubmed.ncbi.nlm.nih.gov/26924491/). Discusses therapeutic targeting strategies.

[Choi et al., MEK-ERK pathway in protein aggregation diseases (2016)](https://pubmed.ncbi.nlm.nih.gov/27292155/). Reviews pathway involvement in proteinopathies.

[Reimers et al., MAPK signaling in synaptic plasticity and memory (2014)](https://pubmed.ncbi.nlm.nih.gov/25227597/). Details role in learning and memory.

[Kim et al., MAP kinase signaling in Parkinson disease (2016)](https://pubmed.ncbi.nlm.nih.gov/26998304/). Reviews PD-specific pathway changes.

[Wang et al., MEK inhibitors for neuroprotection in PD (2017)](https://pubmed.ncbi.nlm.nih.gov/28591052/). Documents neuroprotective effects in PD models.

Pathway Diagram

The following diagram shows the key molecular relationships involving MAP2K1 Gene discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

MAP2K1

▸Metadataorigin_type: v1_polymorphic_backfill

slug	genes-map2k1
kg_node_id	MAP2K1
entity_type	gene
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-158f9c0864a5
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'genes-map2k1'}
_schema_version	1

📊 Evidence Profile

Evidence Balance

+0%

Certainty

35%

Debates

0

Incoming

7

Outgoing

23

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

MAP2K1 Gene

MAP2K1 — Mitogen-Activated Protein Kinase Kinase 1

MAP2K1 — Mitogen-Activated Protein Kinase Kinase 1

Overview

Gene Information

Protein Overview

Protein Structure

Normal Physiological Functions

Neuronal Development

Synaptic Plasticity

Cellular Survival

Role in Alzheimer's Disease

MAPK Pathway Dysregulation

Therapeutic Implications

Molecular Interactions

Role in Parkinson's Disease

Dopaminergic Neuron Vulnerability

Neuroprotective Strategies

Role in Other Neurodegenerative Diseases

Amyotrophic Lateral Sclerosis (ALS)

Huntington's Disease (HD)

Frontotemporal Dementia (FTD)

Genetic Disorders

Cardiofaciocutaneous Syndrome (CFC)

Noonan Syndrome

Therapeutic Targeting

MEK Inhibitors in Neurodegeneration

Clinical Trials

Biomarkers

Signaling Cascade

Cross-references

See Also

External Links

References

Pathway Diagram

💬 Discussion